Mutual of America Capital Management LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 3.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,374 shares of the life sciences company’s stock after buying an additional 563 shares during the period. Mutual of America Capital Management LLC’s holdings in Illumina were worth $3,135,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of ILMN. Jennison Associates LLC raised its stake in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Edgewood Management LLC raised its stake in shares of Illumina by 33.6% in the fourth quarter. Edgewood Management LLC now owns 6,639,776 shares of the life sciences company’s stock worth $850,157,000 after buying an additional 1,671,293 shares during the last quarter. Norges Bank acquired a new stake in shares of Illumina during the fourth quarter worth about $140,899,000. Capital World Investors raised its stake in shares of Illumina by 37.1% in the third quarter. Capital World Investors now owns 2,006,100 shares of the life sciences company’s stock worth $364,428,000 after buying an additional 543,100 shares during the last quarter. Finally, Viking Global Investors LP acquired a new stake in shares of Illumina during the fourth quarter worth about $44,810,000. Institutional investors and hedge funds own 96.85% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 0.10% during mid-day trading on Friday, reaching $171.86. 1,245,906 shares of the company’s stock traded hands. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $189.48. The company’s 50-day moving average price is $179.02 and its 200-day moving average price is $162.35. The stock has a market capitalization of $25.09 billion, a PE ratio of 34.78 and a beta of 0.76.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million for the quarter, compared to analyst estimates of $590.51 million. During the same period in the prior year, the business posted $0.71 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. Analysts anticipate that Illumina, Inc. will post $3.63 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) Stake Increased by Mutual of America Capital Management LLC” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/06/16/mutual-of-america-capital-management-llc-purchases-563-shares-of-illumina-inc-ilmn-updated-updated.html.
A number of equities research analysts have issued reports on ILMN shares. Piper Jaffray Companies reiterated an “overweight” rating and issued a $187.00 price target (up previously from $170.00) on shares of Illumina in a research note on Friday, April 14th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective for the company in a research report on Tuesday, April 4th. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $187.82 price objective for the company in a research report on Monday, March 20th. Cantor Fitzgerald raised their price objective on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a research report on Wednesday, April 26th. Finally, Leerink Swann restated a “buy” rating on shares of Illumina in a research report on Wednesday, April 5th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Illumina has a consensus rating of “Hold” and an average target price of $165.02.
In other Illumina news, Director Daniel Bradbury sold 600 shares of the stock in a transaction that occurred on Tuesday, March 21st. The shares were sold at an average price of $163.56, for a total transaction of $98,136.00. Following the sale, the director now directly owns 17,065 shares in the company, valued at approximately $2,791,151.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Omead Ostadan sold 1,672 shares of the stock in a transaction that occurred on Friday, March 24th. The stock was sold at an average price of $170.00, for a total transaction of $284,240.00. Following the sale, the executive vice president now owns 29,586 shares in the company, valued at $5,029,620. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,057 shares of company stock worth $13,859,634. Company insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.